Antiviral Drugs - Myanmar

Myanmar

The revenue in Myanmar's Antiviral Drugs market is estimated to reach US$9.26m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.71%, leading to a market volume of US$10.08m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$30,640.00m in 2024.
Myanmar is experiencing a surge in demand for antiviral drugs due to the increasing prevalence of viral infections.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Myanmar is experiencing growth due to various factors that have contributed to its development in recent years.

Customer preferences: Customers in Myanmar are becoming increasingly aware of the importance of antiviral drugs, especially with the emergence of new viruses and pandemics. They are more willing to invest in antiviral drugs to protect themselves and their families from these diseases. Additionally, the government's initiatives to promote healthcare and improve access to medicine have also increased demand for antiviral drugs in the country.

Trends in the market: The Antiviral Drugs market in Myanmar is witnessing an increase in the number of market players and a rise in the availability of antiviral drugs. This can be attributed to the growing demand for antiviral drugs and the government's efforts to improve healthcare infrastructure in the country. The market is also witnessing a shift towards the development of generic antiviral drugs due to their affordability and accessibility.

Local special circumstances: Myanmar is a developing country with a large population that lacks access to basic healthcare facilities. The government has been working to improve healthcare infrastructure, but the progress has been slow. This has resulted in a growing demand for antiviral drugs, especially in rural areas where access to healthcare is limited. Additionally, the country's geographical location and proximity to regions with a high prevalence of infectious diseases have also contributed to the growth of the Antiviral Drugs market in Myanmar.

Underlying macroeconomic factors: Myanmar's economy is growing, and this has led to an increase in disposable income and healthcare spending. This has resulted in a rise in demand for antiviral drugs as people are more willing to invest in their health. Additionally, the government's initiatives to promote healthcare and improve access to medicine have also contributed to the growth of the Antiviral Drugs market in Myanmar.In conclusion, the Antiviral Drugs market in Myanmar is experiencing growth due to various factors such as customer preferences, local special circumstances, and underlying macroeconomic factors. The market is witnessing an increase in the number of market players and a shift towards the development of generic antiviral drugs. With the government's continued efforts to improve healthcare infrastructure in the country, the Antiviral Drugs market in Myanmar is expected to grow further in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.